Harding M, Kennedy R, Mill L, MacLean A, Duncan I, Kennedy J, Soukop M, Kaye S B
Department of Medical Oncology, University of Glasgow, UK.
Br J Cancer. 1988 Nov;58(5):640-3. doi: 10.1038/bjc.1988.276.
Forty-six patients with previously untreated, advanced ovarian cancer received carboplatin (JM8, CBDCA) and chlorambucil (CLB) to assess the efficacy and toxicity of this combination. Carboplatin 300 mg m-2 was given on day 1 with CLB 10 mg daily for 7, 10 or 14 days; 6 treatment courses were given at 4-6 weekly intervals in the absence of disease progression. Tumour response was assessed, where possible, by restaging laparotomy after 6 treatment cycles. Five complete and 16 partial remission were seen in 37 evaluable patients giving an overall response rate of 57%. The median survival of all patients was 15 months. The major toxicity was myelosuppression. Nausea and vomiting were generally minor (WHO, grades I or II) and most courses were given on an outpatient basis. Leucopenia was the major factor causing treatment delays, particularly with the 10 and 14 day CLB regimens. Thrombocytopenia was minimal in the early chemotherapy cycles but the data suggest that cumulative toxicity may occur. This combination may provide a satisfactory degree of efficacy with less toxicity than cisplatin-based regimens.
46例既往未接受过治疗的晚期卵巢癌患者接受了卡铂（JM8，CBDCA）和苯丁酸氮芥（CLB）治疗，以评估该联合方案的疗效和毒性。第1天给予卡铂300mg/m²，同时每日给予CLB 10mg，持续7、10或14天；在疾病未进展的情况下，每4 - 6周进行6个疗程的治疗。在可能的情况下，6个治疗周期后通过再次分期剖腹手术评估肿瘤反应。在37例可评估患者中，观察到5例完全缓解和16例部分缓解，总缓解率为57%。所有患者的中位生存期为15个月。主要毒性为骨髓抑制。恶心和呕吐一般较轻（世界卫生组织分级为I级或II级），大多数疗程在门诊进行。白细胞减少是导致治疗延迟的主要因素，尤其是在CLB治疗10天和14天的方案中。在化疗早期周期血小板减少很轻微，但数据表明可能会出现累积毒性。该联合方案可能提供令人满意的疗效程度，且毒性比基于顺铂的方案小。
